Clinical Cancer Research · 2005 · 97 citations · 22 references
The early antiangiogenic activity of SU11248 was detected in vivo by DCE-MRI techniques using either macromolecular or low molecular weight contrast agents. Because DCE-MRI techniques with low molecular weight contrast agents can be used in clinical studies, these results could be relevant for the design of clinical trials based on new paradigms.
22
Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 856 citations · Full text
Leonard Berlin · American Journal of Roentgenology · 1998 · 273 citations
Marc D. Ogan, Udo P. Schmiedl, Michael E. Moseley et al. · Investigative Radiology · 1987 · 272 citations